Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Case Report: Partial Uniparental Disomy Unmasks a Novel Recessive Mutation in the LYST Gene in a Patient With a Severe Phenotype of Chédiak-Higashi Syndrome

  • Boluda-Navarro, Mireia
  • Ibáñez, Mariam
  • Liquori, Alessandro
  • Franco Jarava, Clara
  • Rodríguez-Vega, Héctor
  • Colobran Oriol, Roger
  • Martínez Gallo, Mónica
Síndrome de Chédiak-Higashi; LYST; Disomia uniparental, Síndrome de Chédiak-Higashi; LYST; Disomía uniparental, Chédiak-Higashi syndrome; LYST; Uniparental disomy, Chédiak-Higashi syndrome (CHS) is a rare autosomal recessive (AR) immune disorder that has usually been associated to missense, nonsense or indels mutations in the LYST gene. In this study, we describe for the first time the case of a CHS patient carrying a homozygous mutation in the LYST gene inherited as a result of a partial uniparental isodisomy (UPiD) of maternal origin. Sanger sequencing of the LYST cDNA and single nucleotide polymorphism (SNP)-arrays were performed to identify the causative mutation and to explain the molecular mechanism of inheritance, respectively. Partial-UPiD leads to a copy neutral loss of heterozygosity (CN-LOH) of the telomeric region of chromosome 1 (1q41q44), unmasking the potential effect of the mutation detected. The mutation (c.8380dupT) is an insertion located in exon 32 of the LYST gene resulting in a premature stop codon and leading to the loss of all the conserved domains at the C-terminal of the LYST protein. This would account for the severe phenotype observed. We also reviewed the only two previously reported cases of CHS as a result of a uniparental disomy. In this study, we show that the combination of different strategies, including the use of SNP-arrays, is pivotal to fine-tune the diagnosis of rare AR disorders, such as CHS. Moreover, this case highlights the relevance of uniparental disomy as a potential mechanism of CHS expression in non-consanguineous families., This study was supported by research funding from FEDER funds (CIBERONC, CB16/12/00284), Instituto de Salud Carlos III grants PI16/01113, PI17/00660, PI18/1472, PI19/00812 cofinanced by the European Regional Development Fund (ERDF); as well as from the “Conselleria de Educación, Cultura y Deporte” GV/2019/084. MB-N and AL are recipients of a fellowship from the “Asociación Española Contra El Cáncer” and the “Fundación Española de Hematología y Hemoterapia”, respectively.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Case Report, Partial Uniparental Disomy Unmasks a Novel Recessive Mutation in the LYST Gene in a Patient With a Severe Phenotype of Chédiak-Higashi Syndrome

  • Boluda-Navarro, Mireia
  • Ibáñez, Mariam
  • Liquori, Alessandro|||0000-0002-4842-5986
  • Franco-Jarava, Clara|||0000-0002-9788-189X
  • Martínez Gallo, Mónica|||0000-0002-7340-2161
  • Rodríguez-Vega, Héctor
  • Teresa, Jaijo
  • Carreras, Carmen
  • Such, Esperanza|||0000-0001-6892-403X
  • Zúñiga, Ángel
  • Colobrán Oriol, Roger|||0000-0002-5964-536X
  • Cervera, José|||0000-0001-8252-1106
Chédiak-Higashi syndrome (CHS) is a rare autosomal recessive (AR) immune disorder that has usually been associated to missense, nonsense or indels mutations in the LYST gene. In this study, we describe for the first time the case of a CHS patient carrying a homozygous mutation in the LYST gene inherited as a result of a partial uniparental isodisomy (UPiD) of maternal origin. Sanger sequencing of the LYST cDNA and single nucleotide polymorphism (SNP)-arrays were performed to identify the causative mutation and to explain the molecular mechanism of inheritance, respectively. Partial-UPiD leads to a copy neutral loss of heterozygosity (CN-LOH) of the telomeric region of chromosome 1 (1q41q44), unmasking the potential effect of the mutation detected. The mutation (c.8380dupT) is an insertion located in exon 32 of the LYST gene resulting in a premature stop codon and leading to the loss of all the conserved domains at the C-terminal of the LYST protein. This would account for the severe phenotype observed. We also reviewed the only two previously reported cases of CHS as a result of a uniparental disomy. In this study, we show that the combination of different strategies, including the use of SNP-arrays, is pivotal to fine-tune the diagnosis of rare AR disorders, such as CHS. Moreover, this case highlights the relevance of uniparental disomy as a potential mechanism of CHS expression in non-consanguineous families.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

  • Álvarez Larrán, Alberto|||0000-0001-6387-4619
  • Garrote, Marta
  • Ferrer-Marín, Francisca|||0000-0002-9520-3243
  • Pérez-Encinas, Manuel|||0000-0001-9943-4404
  • Mata-Vazquez, M.Isabel
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Arellano-Rodrigo, Eduardo|||0000-0001-6236-7826
  • Gómez, Montse
  • García, Regina
  • García Gutiérrez, Valentín|||0000-0003-4752-0815
  • Gasior Kabat, Mercedes
  • Cuevas, Beatriz|||0000-0001-7555-3361
  • Angona, Anna|||0000-0002-0965-9501
  • Gómez-Casares, María Teresa
  • Martínez, Clara
  • Magro, Elena
  • Ayala, Rosa|||0000-0002-2699-8353
  • Del Orbe Barreto, Rafael Andrés|||0000-0002-1240-1958
  • Pérez-López, Raúl
  • Fox, Maria Laura|||0000-0002-0062-6607
  • Raya, José-Maria
  • Guerrero, Lucía
  • García-Hernández, Carmen
  • Caballero, Gonzalo
  • Murillo, Ilda
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Ramírez, M.José
  • Carreño-Tarragona, Gonzalo|||0000-0002-9570-5542
  • Hernandez-Boluda, Juan Carlos|||0000-0002-4289-3113
  • Pereira, Aarturo
Background: Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown. Methods: A retrospective, real-world analysis was performed on the outcomes of 377 patients with resistance/intolerance to hydroxyurea from the Spanish Registry of Polycythemia Vera according to subsequent treatment with ruxolitinib (n = 105) or the best available therapy (BAT; n = 272). Survival probabilities and rates of thrombosis, hemorrhage, acute myeloid leukemia, myelofibrosis, and second primary cancers were calculated according to treatment. To minimize biases in treatment allocation, all results were adjusted by a propensity score for receiving ruxolitinib or BAT. Results: Patients receiving ruxolitinib had a significantly lower rate of arterial thrombosis than those on BAT (0.4% vs 2.3% per year; P =.03), and this persisted as a trend after adjustment for the propensity to have received the drug (incidence rate ratio, 0.18; 95% confidence interval, 0.02-1.3; P =.09). There were no significant differences in the rates of venous thrombosis (0.8% and 1.1% for ruxolitinib and BAT, respectively; P =.7) and major bleeding (0.8% and 0.9%, respectively; P =.9). Ruxolitinib exposure was not associated with a higher rate of second primary cancers, including all types of neoplasia, noncutaneous cancers, and nonmelanoma skin cancers. After a median follow-up of 3.5 years, there were no differences in survival or progression to acute leukemia or myelofibrosis between the 2 groups. Conclusions: The results suggest that ruxolitinib treatment for PV patients with resistance/intolerance to hydroxyurea may reduce the incidence of arterial thrombosis. Lay Summary: Ruxolitinib is better than other available therapies in achieving hematocrit control and symptom relief in patients with polycythemia vera who are resistant/intolerant to hydroxyurea, but we still do not know whether ruxolitinib provides an additional benefit in preventing thrombosis or disease progression. We retrospectively studied the outcomes of 377 patients with resistance/intolerance to hydroxyurea from the Spanish Registry of Polycythemia Vera according to whether they subsequently received ruxolitinib (n = 105) or the best available therapy (n = 272). Our findings suggest that ruxolitinib could reduce the incidence of arterial thrombosis, but a disease-modifying effect could not be demonstrated for ruxolitinib in this patient population.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Case Report: Partial Uniparental Disomy Unmasks a Novel Recessive Mutation in the LYST Gene in a Patient With a Severe Phenotype of Chédiak-Higashi Syndrome

  • Boluda-Navarro, Mireia
  • Ibáñez, Mariam
  • Liquori, Alessandro
  • Franco Jarava, Clara
  • Rodríguez-Vega, Héctor
  • Colobran Oriol, Roger
  • Martínez Gallo, Mónica
Síndrome de Chédiak-Higashi; LYST; Disomia uniparental, Síndrome de Chédiak-Higashi; LYST; Disomía uniparental, Chédiak-Higashi syndrome; LYST; Uniparental disomy, Chédiak-Higashi syndrome (CHS) is a rare autosomal recessive (AR) immune disorder that has usually been associated to missense, nonsense or indels mutations in the LYST gene. In this study, we describe for the first time the case of a CHS patient carrying a homozygous mutation in the LYST gene inherited as a result of a partial uniparental isodisomy (UPiD) of maternal origin. Sanger sequencing of the LYST cDNA and single nucleotide polymorphism (SNP)-arrays were performed to identify the causative mutation and to explain the molecular mechanism of inheritance, respectively. Partial-UPiD leads to a copy neutral loss of heterozygosity (CN-LOH) of the telomeric region of chromosome 1 (1q41q44), unmasking the potential effect of the mutation detected. The mutation (c.8380dupT) is an insertion located in exon 32 of the LYST gene resulting in a premature stop codon and leading to the loss of all the conserved domains at the C-terminal of the LYST protein. This would account for the severe phenotype observed. We also reviewed the only two previously reported cases of CHS as a result of a uniparental disomy. In this study, we show that the combination of different strategies, including the use of SNP-arrays, is pivotal to fine-tune the diagnosis of rare AR disorders, such as CHS. Moreover, this case highlights the relevance of uniparental disomy as a potential mechanism of CHS expression in non-consanguineous families., This study was supported by research funding from FEDER funds (CIBERONC, CB16/12/00284), Instituto de Salud Carlos III grants PI16/01113, PI17/00660, PI18/1472, PI19/00812 cofinanced by the European Regional Development Fund (ERDF); as well as from the “Conselleria de Educación, Cultura y Deporte” GV/2019/084. MB-N and AL are recipients of a fellowship from the “Asociación Española Contra El Cáncer” and the “Fundación Española de Hematología y Hemoterapia”, respectively.